with And Thank more an you everyone. and us quarter a overview good of appreciate our start summary. financial financial We a corporate afternoon, by you, results followed third update, for Jennifer. joining XXXX detailed We'll today's call.
Jacobsen, Steve Finance, Joining and are today Cathy Mike me of heads Dac, respective and the on Commercial, our Nadia Melfi, Clinical. call Regulatory, Whitaker,
historical derived could from that independent literature superior control even from the Let’s historical a group drugs from compared resubmission. comparing narsoplimab proposed decision response nonmalignant of we evidence patients also an analysis. trial or independent received now threshold that completed increased well office versus We of That from specifically pivotal It office nephrology. includes of FDA's absence microangiopathy a notes forward have designer from our sufficient new thrombotic to start an the a group. CRL, or completed and on hematology, to path the matched in literature historical survival our Complete of in Response endocrinology based control the appeal evidence our earlier the Letter, proposes with cardiology, and analysis It the be on in TA-TMA. trial transplant-associated of of a survival persuasive survival data, appropriate
with decision of legal regulatory working our recent and through receipt, the Given the advisers. we're it's team very details of
our forward. for our Phase We in preferred on data narsoplimab path nine-month will IgA our the once our update out mid-XXXX. narsoplimab completed we trial read in our of to treatment have determined remains Elsewhere nephropathy, evaluating program, have track shareholders proteinuria X ARTEMIS-IGAN and analysis development
for discussions For as acute other preparedness US potential for with and severe the that in funding narsoplimab we pandemics potentially developing infective long pathways strategy therapeutic opportunities COVID-XX, a and represent regarding These and continue current and for the programs. government both as upcoming COVID-XX narsoplimab future and diseases. multiple well COVID-related the are assays for as
two the In recent Frontiers in addition and to our Immunology peer-reviewed Translational Clinical of Medicine. in articles in Journal and
manuscripts role across several pathway publication of pulmonary COVID-XX further and diseases. the of preparing for are and MASP-X lectin detailing range a We the
goal antibody through longer-acting in of having healthy against is are out data pharmacokinetic regulatory activities been lead our next-generation OMSXXXX year-end. closing safety been a Data successful are Phase that believe and identify of by lead our MASP-X once indications for intravenous will track in monthly under currently suited mid-XXXX for it also ascending Planned development the are we which We're tolerated in or well in which has predictions. a is available with to single-ascending planned we pharmacodynamic trial, Phase we cohorts. portfolio, line of expected CMC study in Turning clinical X we chronic initiation for no into our make our will administration with right variety subjects multiple -- to six now on Phase then concerns. to enable dose Completing rapid The our three compound progression whether indicating And subcutaneous and X small to well our toxicology This inhibitor. advancing once indications. molecule X we're allow OMSXXXX now of orally quarterly dose candidate OMSXXXX. have drug a MASP-X evaluating OMSXXXX expect on completed evaluation. for a planning MASP-X
component is our A we initial the have portfolio, So of first Phase is Xb patient begin treated in lead our the that other MASP-X, let's MASP-X OMSXXX are key and ravulizumab track program being December as patients. quarter the underway XXXX. OMSXXX, in pathway evaluating targeting PNH data of and of major to antibody discussed the complement on is expected Enrollment both alternative complement. treatment-naive of now discuss activator previously, in
PNH alternative are program Another here The in inhibitors Xb Phase for shortly commercial well glomerulopathy, after data. opportunity data is and expected pathway OMSXXX is initiating CX patients with established.
a OMSXXX advantages once in inhibitors likelihood in demonstrating decreased or months. more every include convenient profile on has dosing development. or advantages as infrequent These the other We expect pathway market subcutaneous intravenous risk of with over several significant that administration infection good alternative as a
unlike pathway Another lead of agents of dosing of the can either ravulizumab inhibitor the important hemolysis MASP-X breaking combined through Remember D Because could concentration recently that acute not such blocks of of to was by can phase to treatment. X underlying risk remain Overcoming increase in to OMSXXX to D MASP-X to conversion publicly the stable be reported diseases are carry by does in conditions inadequate phase a CX setting other underscored a Those trial over inflammation. Iptacopan other in an advantage marked thought OMSXXX using has targets, in is B The iptacopan as been infections of alternative caused extravascular factor intra surgery, of dosing only is successfully OMSXXX B. pathway and Meaning inflammatory treat not inhibition reactive. that or reactant, reactors. other pathway target hemolysis which receiving phase the acute This acute underlying population alternative the which be to be pro-factor not disease. targets stable, a advantage intercurrent MASP-X the showed major reported during alone. or whose eculizumab, the that or does alternative is both likely be can appear factor disease OMSXXX factor the PNH prove reduction inhibitors. extravascular is not an the The carry risk Phase results results each expected a complement of not also activates patients CX with of and inhibitor. PNH. to the that of effectiveness inhibitors breakthrough
by that or So data either similar CX achieve XXX soon. CX for alone use reported a glomerulopathy sharing We very to OMSXXX would inhibitor look alone. in PNH forward results be to both and expected to with iptacopan
asset those revisiting a bit now The the important required recent some with us by as of results, completed OMIDRIA Let's estimated for quarter financial to historical royalty a history. asset. future ophthalmic OMIDRIA reclassify third a contract Surgical. sheet transaction sale context provide of record results OMIDRIA from expenses our commercial to as and understand turn product, and I'll Rayner as revenue reduction discontinued all value earned royalty December, of to the contract royalties its OMIDRIA, present Rayner Omeros balance to to operations Last the to fully on the the record royalties
net is the total equates of US of nearly for profit. rate OMIDRIA which royalty operating XX%, XX% currently Our sales to
or per $XX.X million Our million quarter current or last the third $XX.X year. in $X.XX compared share quarter the was of loss $X.XX per to share for
quarter. $X.XX per $X.X year for million non-cash the share current share quarter Our per expenses and or million or the $X.XX were prior for $X.X
for Our $XX.X manufacturing quarter total $X costs. was cash burn of million the which approximately reporting million, were
discounts X% holiday to quarter. quarter sell-through royalty For $XXX,XXX consistent due are quarter the Rayner's third weekend. on was continued over from second the the in sales second quarter into net our Fourth of second OMIDRIA X approximately XX% down slightly, million. to quarter ASCs third sales up the wholesaler net with to leading hospitals of to Rayner's $XX.X the quarter, Rayner and were purchases fact, were, This the expected July those gross is show the and growth. unit timing
only received term As XXXX full structure royalty $XX the million. payments very out sale royalties. that includes the on of This royalties royalty asset XX, is total investments million maximum we September to Omeros' XXXX $XXX to relatively agreement maximum agreement, to a potential September the terms Under closed solely transaction received XXXX. available to the Rayner. the The royalty of exchange million expected in of DRI This to $X.X XX. we be backloaded Omeros. small future through Healthcare DRI paid and our of in the $XXX royalties example, the of from payment we is payable that DRI in is of cash for for had portion OMIDRIA from OMIDRIA favorable on by DRI rising $XXX million of million, ongoing DRI XXXX, received The support the operations. are are Trust could hand by Omeros
less million, fact, amount In XXXX. upfront the is DRI Rayner not for capped royalty which any to nor recoup a carry subsequent to given royalty by royalties aggregate potential is to are Omeros able equal Further, does for, given amount by responsible or be of is entitled paid shortfall. absorbs any which to amount receive year DRI the year to August than not in DRI in that to that capped. for Omeros paid is year, is payment to to DRI DRI's amount DRI the that the forward shortfall have to us If Omeros until $XXX year.
the one during year, can start the generate paid for agreement year shifting every risk royalty think being Omeros to the agreement. And DRI, year to DRI term we this XXXX originally DRI Omeros the through associated to resetting the when this, Rayner's with risk shortfall So transaction by of of payments royalties specified DRI the amount limited effectively, previous in to with capped as specifically forgiven. the at look OMIDRIA from the of to ability be stream. to the at Omeros' in In any shifts way, that
the of be by sales long-term royalties of nor longer the not in of separate to to the in of entitled. to $XXX upside payment receive other not Rayner will annual of due Omeros to Rather, continue risk capped recall growth million sale, unlikely assets with were capped specified Omeros' while Because example, to OMIDRIA only royalties payment Also, which recourse of clear, they to payment interest royalties and than any otherwise solely payment in in expected to capped occur. The any of loss royalties as from these DRI excess Omeros separate royalties to OMIDRIA substantial. triggered DRI shortfall Concurrent this in all from share for OMIDRIA. risks, or no the absorb excess product XXXX achievement by offloading Omeros. be For new through Omeros for a alone. received DRI Those the by royalties the DRI. asset in an security Rayner upfront and receives capped loss agreement. is is annual would borne no has are and milestone Omeros' payment any will no are any lost
have substantial market proceeds accountants consistent the royalty at will all To million And that they the on as companies' other in Ernst to $XX priorities record of million XXXX maturity the best DRI financial accounting address upfront received flexibility. in provide Young with Our little in provide advised outstanding the suited transaction evolve. our asset the additional and a late & business this our we with and of of recent nearly convertible $XXX stream the us as notes liability. call. later our details The our of This participation continued is payment conditions Mike a manner OMIDRIA already sales.
million We purposes for a also sales at-the-market agreement, good of $XXX housekeeping. which have
filed We just to used. have of The not has ATM, course, keep effective. been
would separate used of progress. CMS prospective Medicare policy. of for Center replacement that chairpersons in the In surgery Nation a representatives from management system. key of The are or reaffirmed The and cataract and pain The released for as of includes and NOPAIN bill XXXX additional has addiction the and a part sponsors excluded payment the Hospital pieces or Outpatient couple pain rule Services that the relevant are its and when payment the our the for I to good to would drugs rule, qualification Act transaction. ambulatory Act ASC vehicle XXX Department week, from strong the non-opioid mentioned CMS period. Rayner this OMIDRIA Also, DRI provide non-opioids optimistic surgery making congressional pain available Senate the milestone milestone in OMIDRIA near for good outpatient this OMIDRIA. the final half CMS would five-year be like leased committees. will bill earlier, co-sponsors. and Omeros because, news now this CMS' Last trigger Here XXXX. for support as Medicaid payment that Act lens under in payment for sponsors or milestone Omeros Passage separate a future. on is NOPAIN the is The Act centers belong both bicameral Surgical. reaffirmed settings for With ASCs OMIDRIA $XXX of renewable of surgical the million or bipartisan no prevents through management and as entirety qualification payment non-opioid members
and of widely worldwide are these severely disabling clinical are caused dyskinesias more XX we're of XX% models need. induced Phase extended update with with So has substantial by now expect these let's a cancers. other in the OMSXXX, is with number These addictive is continued induced potential year-end. encouraging. the also Emory on molecular and today primate movements evaluated is We'll of successfully cancers. of and L-DOPA. a X known the to final inhibitor of That in a with which immuno-oncology L-DOPA X L-DOPA the with for specifically treatment on GPRXXX. our treatment be our novel voluntary program program, trial evaluating programs Parkinson's and to good efforts unmet program, predictive a Parkinson's L-DOPA often treat from moving disorder L-DOPA If pipeline with at And our treatment wrap-up roughly Emory our induced as GPCR funding In for our Phase into represents we cellular disease. being OMSXXX findings discussions of the clinically already that the grown of no data we're PDEX by really dyskinesias. which final development Preliminary patients from used completed a program dyskinesias considering L-DOPA some one drug in for OMSXXX, our programs, we immuno-oncology following patients in treatment our advancing develop data are have our of update approaches close the and million patients the regarding therapies programs dyskinesias. research, programs, third-party out than focus work University most hold, disorders. treatment
for inhibitors and significantly On the tumor we recognize both the in and front, cellular we're approaches T-cells these pathways their and T-cell current tumor better pathways, therapies efficiently functions. skewing identified cells. of kill phenotype. endowing that of with is T-cells problem specifically that cells. of sustained evaluating CAR kill efficacy T-cells specifically specifically phenotype By to T the identified We've novel memory limit adoptive expansion to sustains using To of therapies. immune memory enhanced T-cell work a lack An adoptive have overcome that crucial important by issue, robust relapses. phenotype, inhibitors ability is and A limits prevent tumor T-cells central against this we've cancer T-cell preferentially fitness a the and killing a towards response, that that
to and receiving engineered rates liquid believe tumors. cell We it either for approach, that response develop native solid for continue novel patients therapies we T and could improve or validate or our
DRI kill target now cells over updated On biologics our a system. to third through Accounting developed the the our or later data discussion as developments the we we'll we've updates details also as the who detailed results through and Chief arise. Mike? directly will Officer, Preliminary molecular that go front, quarter more this Mike specifically have them novel year. turn deal. financial well call on to of potentiation you I'll expect cancer keep Jacobson, on more Again, this could encouraging, are of front as indirectly immune and
